Evidence map›Paper›PMID 32946821›Full record

Trial reportThe lancet. Diabetes & endocrinology2020

Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.

Per-Henrik Groop, Paresh Dandona, Moshe Phillip, Pieter Gillard, Steven Edelman, Johan Jendle, John Xu, Markus F Scheerer, Fredrik Thoren, Nayyar Iqbal and 2 more

Abstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The lancet. Diabetes & endocrinology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 6 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 6 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD.Journal of the American Society of Nephrology : JASN · 2025
    Article
  16. Article
  17. Article
  18. Sodium-Glucose Co-transporter-2 Inhibitors in Type 1 Diabetes Mellitus: The Framework for Recommendations for Their Potential Use.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024
    Article
  19. Article
  20. The emergence of obesity in type 1 diabetes.International journal of obesity (2005) · 2024
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 7 countries.

Per-Henrik GroopAbdominal Center, Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland; Department of Diabetes, Central Clinical School, Monash University, Melbourne, VIC, Australia.
Paresh DandonaJacob School of Medicine, State University of New York, Buffalo, NY, USA.
Moshe PhillipInstitute for Endocrinology and Diabetes, Schneider Children's Medical Center of Israel, Petah Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Pieter GillardClinical and Experimental Endocrinology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium.
Steven EdelmanDepartment of Medicine, University of California, San Diego, CA, USA.
Johan JendleInstitute of Medical Sciences, Örebro University, Örebro, Sweden.
John XuLate-stage Development, Cardiovascular, Renal and Metabolism, AstraZeneca, Gaithersburg, MD, USA.
Markus F ScheererBioParmaceuticals Medical, AstraZeneca, Wedel, Germany.
Fredrik ThorenLate-stage Development Cardiovascular, Renal and Metabolism, AstraZeneca, Gothenburg, Sweden.
Nayyar IqbalLate-stage Development, Cardiovascular, Renal and Metabolism, AstraZeneca, Gaithersburg, MD, USA.
Enrico RepettoGlobal Medical Affairs, AstraZeneca, Gaithersburg, MD, USA.
Chantal MathieuClinical and Experimental Endocrinology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium. Electronic address: chantal.mathieu@uzleuven.be.
AstraZeneca (United States) · USKU Leuven · BEAstraZeneca (Germany) · DEAstraZeneca (Sweden) · SEFolkhälsans Forskningscentrum · FIÖrebro University · SESchneider Children's Medical Center · ILUniversity at Buffalo, State University of New York · USUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe DEPICT-1 and DEPICT-2 studies showed that dapagliflozin as an adjunct to insulin in individuals with inadequately controlled type 1 diabetes improved glycaemic control and bodyweight, without increase in risk of hypoglycaemia. We aimed to determine the effect of dapagliflozin on urinary albumin-to-creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) using pooled data from the DEPICT studies.

methodsIn this post-hoc analysis, we used data pooled from both DEPICT studies (DEPICT-1 ran from Nov 11, 2014, to Aug 25, 2017; DEPICT-2 ran from July 8, 2015, to April 18, 2018), in which participants were aged 18-75 years, with inadequately controlled type 1 diabetes and with a baseline UACR of at least 30 mg/g. In the DEPICT studies, participants were randomly assigned (1:1:1) to receive dapagliflozin (5 mg or 10 mg) or placebo all plus insulin, for 24 weeks, with a 28-week long-term extension (ie, 52 weeks in total). In this post-hoc analysis, we assessed the percentage change from baseline in UACR and in eGFR, up to 52 weeks. UACR, eGFR, and safety were assessed in all eligible participants who had received at least one dose of study drug. HbA

results251 participants with albuminuria at baseline were included in this post-hoc analysis; of whom 80 (32%) had been randomly assigned to dapagliflozin 5 mg, 84 (33%) to dapagliflozin 10 mg, and 87 (35%) to placebo. Compared with placebo, treatment with both dapagliflozin doses improved UACR over 52 weeks. At week 52, mean difference in change from baseline versus placebo in UACR was -13·3% (95% CI -37·2 to 19·8) for dapagliflozin 5 mg and -31·1% (-49·9 to -5·2) for dapagliflozin 10 mg. No notable change from baseline was seen in eGFR, with a mean difference in change from baseline versus placebo of 3·27 mL/min per 1·73 m

interpretationTreatment with dapagliflozin resulted in UACR reduction, which might provide renoprotective benefits in individuals with type 1 diabetes and albuminuria. Dedicated prospective studies are needed to confirm these findings as prespecified endpoints.

fundingAstraZeneca.

Indexed as

AdolescentAdultAgedAlbuminuriaBenzhydryl CompoundsBiomarkersBlood GlucoseCreatinineDiabetes Mellitus, Type 1Diabetic KetoacidosisDouble-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesGlomerular Filtration RateGlucosidesBenzhydryl CompoundsBiomarkersBlood GlucoseCreatininedapagliflozinGlucosidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulinSodium-Glucose Transporter 2 Inhibitors

Identifiers

PMID32946821
OpenAlexW3086148163

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.